We are live on ! Find out more

AbbVie

ABBV

Market cap $521B

294.83 USD

+8.83

3.09%

At close Updated Nov 4, 4:00 PM EST

Pre-market

After hours

295.18

+0.35

0.12%

1 day

3.09%

5 days

1.32%

1 month

10.94%

3 months

20.93%

6 months

41.64%

Year to date

28.57%

1 year

36.56%

5 years

151.86%

10 years

426.11%

About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.

Employees: 57,000

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 56.6%

Neutral 39.8%

Negative 3.5%

Zacks Investment Research

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

24/7 Wall Street

Exxon Mobil Just Raised Its Dividend for the 44th Year. Here Are 3 More Wall Street Favorites

Four dividend stocks just delivered strong earnings, but free cash flow and balance sheet strength separate the ones built to keep raising payouts from the ones that just look good on paper.

Exxon Mobil Just Raised Its Dividend for the 44th Year. Here Are 3 More Wall Street Favorites

Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)

I monitor dividend increases and cuts across 1,200+ stocks, focusing on dividend growth streaks, safety, and valuation to identify conviction opportunities. V, APH, and HIG stand out for robust dividend hikes, high-quality scores, and strong safety metrics. Energy names XOM and MPLX offer high yields and long growth streaks, but MPLX and SCL raise coverage and safety concerns because of their high payout ratios.

Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)

AbbVie expands Oxford R&D facility as part of £120 million-plus investment

AbbVie has expanded its UK research and development facility in Oxford as part of a more than £120 million ($161 million) investment, ‌the US drugmaker said on Wednesday.

AbbVie expands Oxford R&D facility as part of £120 million-plus investment

24/7 Wall Street

AbbVie Hit a New High After Earnings. There's More Upside Left.

AbbVie just logged a 33% gain for the year and raised its guidance again, but the real question is whether Skyrizi and a newly closed pipeline deal can push shares even further past a valuation that already looks stretched.

AbbVie Hit a New High After Earnings. There's More Upside Left.

Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

– Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial outcomes – A digital image analysis evaluating glabellar line severity and brow position following treatment with investigational trenibotulinumtoxinE (trenibotE) and BOTOX ® Cosmetic (onabotulinumtoxinA) will be presented during the Cosmetic Oral Abstract Presentations: Top Ten session – Expert panel to explore shifting consumer expectations, common misconceptions and medical weight loss in aesthetics, drawing on insights from the Allergan Aesthetics "What Consumers Really Want" report IRVINE, Calif., Nov. 3, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, Nov. 5-8 in San Diego, underscoring the company's continued investment in generating scientific evidence to inform care across multiple aesthetic categories.

Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test

AbbVie TodayABBVAbbVie$288.82 -6.07 (-2.06%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$190.75▼$298.74Dividend Yield2.40%P/E Ratio49.69Price Target$285.89Add to WatchlistBelieve it or not, Humira still drives headlines for AbbVie NYSE: ABBV, despite contributing little to the company's growth.

AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test

The Motley Fool

The Best Dividend Stocks to Buy With $5,000 in November

AbbVie survived its loss of Humira, and its profits are soaring. J&J's streamlining efforts are paying off.

The Best Dividend Stocks to Buy With $5,000 in November

Zacks Investment Research

ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress

AbbVie raises its 2026 revenue and earnings outlook as Skyrizi, Rinvoq and neuroscience growth fuel momentum, while oncology milestones shape prospects.

ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress

The Motley Fool

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

AbbVie is successfully navigating a critical transition period as newer immunology drugs offset revenue declines from legacy products. Bristol Myers Squibb offers a high-margin portfolio focused on oncology and hematology with a significantly lower valuation multiple.

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

See News Rankings

Price charts implemented using Lightweight Charts™